Aalto Bio Reagents, a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry, has been acquired Swiss company Biosynth Carbosynth .

Deal consideration was not disclosed.

Aalto Bio Reagents, founded in 1978, supplies customers with a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-vitro diagnostic application.

CEO Philip Noone led an MBO in 2014, and the business recently won the main award in the Small Firms Association National Small Business Awards 2022.

Based in Staad in Switzerland, Biosynth Carbosynth is owned by private equity companies including by KKR.

In Association with

Biosynth has expertise in enzyme substrates, carbohydrate, nucleoside chemistry and custom peptide synthesis.

Philip Noone commented: “We are thrilled to be joining forces with Biosynth, a world-renowned supplier with a broad portfolio of critical products and services across biopharma and diagnostics.

"Aalto’s industry leading products and key focus on emerging disease are an excellent fit with Biosynth’s products.

“We see huge opportunities for our combined companies to be at the forefront of developing new innovative products and supplying our customers with an even greater scale and diversity of products they need to solve the diseases of the future.” 

Dr Urs Spitz, CEO of Biosynth, added: “This acquisition marks the next phase of our ambitious journey to become a leading global supplier and partner to the biopharma and diagnostics industries.

“It allows us to offer an expanded range of products to our IVD customers including complex biochemicals, peptides and biological materials.”

Photo: Dr Urs Spitz (left), CEO of Biosynth Carbosynth, and Philip Noone,  CEO of Aalto Bio Reagents